BRAF and neoplasm: In terms of outcomes focus on overall TC, <i>BRAF<sup>V600E</sup></i> + <i>TERT</i> co-mutation ranked highest for diseases stage (OR = 5.74, 95% CrI: 3.09-10.66), as well as lymph node metastasis, extrathyroidal extension (5.74, 4.06-8.10), tumor recurrence (7.21, 3.59-14.47), and invasion of the thyroid capsule (3.11, 1.95-4.95).